BlackRock’s Cumberland Pharmaceuticals CPIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $412K | Buy |
63,547
+6,656
| +12% | +$31.9K | ﹤0.01% | 4629 |
|
|
2026
Q1 | $185K | Buy |
56,891
+4,314
| +8% | +$16.6K | ﹤0.01% | 4791 |
|
|
2025
Q4 | $209K | Buy |
52,577
+448
| +0.9% | +$1.33K | ﹤0.01% | 4713 |
|
|
2025
Q3 | $163K | Buy |
52,129
+961
| +2% | +$3.19K | ﹤0.01% | 4725 |
|
|
2025
Q2 | $171K | Buy |
51,168
+18,510
| +57% | +$87.7K | ﹤0.01% | 4707 |
|
|
2025
Q1 | $138K | Sell |
32,658
-9,923
| -23% | -$41.1K | ﹤0.01% | 4683 |
|
|
2024
Q4 | $101K | Sell |
42,581
-67,487
| -61% | -$99.4K | ﹤0.01% | 4789 |
|
|
2024
Q3 | $141K | Sell |
110,068
-496
| -0.4% | -$686 | ﹤0.01% | 4607 |
|
|
2024
Q2 | $169K | Hold |
110,564
| – | – | ﹤0.01% | 4583 |
|
|
2024
Q1 | $186K | Sell |
110,564
-426
| -0.4% | -$850 | ﹤0.01% | 4599 |
|
|
2023
Q4 | $199K | Hold |
110,990
| – | – | ﹤0.01% | 4639 |
|
|
2023
Q3 | $210K | Sell |
110,990
-2,701
| -2% | -$4.53K | ﹤0.01% | 4663 |
|
|
2023
Q2 | $167K | Sell |
113,691
-18,247
| -14% | -$31.5K | ﹤0.01% | 4774 |
|
|
2023
Q1 | $257K | Sell |
131,938
-8,682
| -6% | -$20.6K | ﹤0.01% | 4706 |
|
|
2022
Q4 | $316K | Buy |
140,620
+270
| +0.2% | +$626 | ﹤0.01% | 4728 |
|
|
2022
Q3 | $338K | Buy |
140,350
+102
| +0.1% | +$240 | ﹤0.01% | 4834 |
|
|
2022
Q2 | $292K | Buy |
140,248
+1,346
| +1% | +$3.11K | ﹤0.01% | 4932 |
|
|
2022
Q1 | $392K | Buy |
138,902
+1,169
| +0.8% | +$3.89K | ﹤0.01% | 4940 |
|
|
2021
Q4 | $643K | Sell |
137,733
-195,318
| -59% | -$666K | ﹤0.01% | 4800 |
|
|
2021
Q3 | $892K | Sell |
333,051
-62,973
| -16% | -$187K | ﹤0.01% | 4589 |
|
|
2021
Q2 | $1.13M | Buy |
396,024
+32,579
| +9% | +$95.8K | ﹤0.01% | 4481 |
|
|
2021
Q1 | $1.1M | Buy |
363,445
+1,034
| +0.3% | +$3.36K | ﹤0.01% | 4471 |
|
|
2020
Q4 | $1.07M | Sell |
362,411
-2,563
| -0.7% | -$7.76K | ﹤0.01% | 4196 |
|
|
2020
Q3 | $1.17M | Buy |
364,974
+7,554
| +2% | +$24.8K | ﹤0.01% | 4072 |
|
|
2020
Q2 | $1.19M | Buy |
357,420
+29,805
| +9% | +$108K | ﹤0.01% | 3998 |
|
|
2020
Q1 | $1.19M | Sell |
327,615
-3,944
| -1% | -$17.7K | ﹤0.01% | 3820 |
|
|
2019
Q4 | $1.71M | Sell |
331,559
-597
| -0.2% | -$3.15K | ﹤0.01% | 3832 |
|
|
2019
Q3 | $1.97M | Sell |
332,156
-387
| -0.1% | -$2.15K | ﹤0.01% | 3760 |
|
|
2019
Q2 | $2.12M | Buy |
332,543
+48,753
| +17% | +$296K | ﹤0.01% | 3765 |
|
|
2019
Q1 | $1.65M | Sell |
283,790
-23,111
| -8% | -$134K | ﹤0.01% | 3770 |
|
|
2018
Q4 | $1.85M | Sell |
306,901
-9,331
| -3% | -$55.8K | ﹤0.01% | 3699 |
|
|
2018
Q3 | $1.8M | Sell |
316,232
-14,086
| -4% | -$83K | ﹤0.01% | 3809 |
|
|
2018
Q2 | $2.02M | Sell |
330,318
-2,164
| -0.7% | -$13.5K | ﹤0.01% | 3734 |
|
|
2018
Q1 | $2.22M | Sell |
332,482
-44,735
| -12% | -$308K | ﹤0.01% | 3653 |
|
|
2017
Q4 | $2.78M | Sell |
377,217
-16,673
| -4% | -$123K | ﹤0.01% | 3608 |
|
|
2017
Q3 | $2.78M | Sell |
393,890
-6,555
| -2% | -$45.3K | ﹤0.01% | 3625 |
|
|
2017
Q2 | $2.8M | Sell |
400,445
-18,182
| -4% | -$120K | ﹤0.01% | 3606 |
|
|
2017
Q1 | $2.9M | Buy |
+418,627
| New | +$2.54M | ﹤0.01% | 3549 |
|
Other funds holding CPIX
VCM
VFT
B
QC
BlackRock's CPIX Position: Q2 2026 in Review
BlackRock increased its Cumberland Pharmaceuticals (CPIX) stake by 12% in Q2 2026, buying an estimated $31.9K and bringing the position to 63,547 shares worth $412K. The position accounts for ﹤0.01% of the portfolio, ranked #4629.
BlackRock first reported a position in CPIX in Q1 2017 and has held it in 38 quarters since. The position peaked at $2.9M in Q1 2017. 20 funds tracked by Wall St. Rank hold CPIX as of Q2 2026.
- BlackRock held 63,547 shares of Cumberland Pharmaceuticals worth $412K as of Q2 2026.
- BlackRock bought 6,656 Cumberland Pharmaceuticals shares in Q2 2026, an estimated $31.9K.
- Cumberland Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4629 holding.
- BlackRock first reported a position in Cumberland Pharmaceuticals in Q1 2017 and has held it in 38 quarters since.
- BlackRock's Cumberland Pharmaceuticals position peaked at $2.9M in Q1 2017.
- 20 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.